Povetacicept Cuts Proteinuria 49.8% in Phase 3 IgAN Trial, FDA Decision Due Nov. 30
VRTX sits 30% above its 52-week low of $403.16 on light trading volume (0.3× avg).
Summary
Vertex's povetacicept hit the primary endpoint in the Phase 3 RAINIER trial in IgA nephropathy, cutting proteinuria 49.8% versus placebo at Week 36 with a p-value below 0.0001. Both secondary endpoints were also met, and 42.2% of patients reached the KDIGO-aligned UPCR threshold under 0.5 g/g, with no related serious adverse events or opportunistic infections. The data are published in NEJM and presented at ASN, which adds external validation beyond a company press release. The FDA is already reviewing the BLA for accelerated approval with a Nov. 30, 2026 PDUFA date, so the regulatory decision is roughly five weeks out. This is a new pipeline asset for Vertex beyond cystic fibrosis, and a clean efficacy and safety package materially raises the odds of approval. Watch the Nov. 30 PDUFA date; longer-term durability on eGFR slope at 104 weeks will drive the commercial case.
At the time of this announcement, VRTX was trading at $525.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $133.3B. The 52-week trading range was $403.16 to $560.25. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.